PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.

Fecha de publicación: 12/05/2020 Fecha Ahead of Print: 12/05/2020

Autores de IIS La Fe

Antonio Conde Moreno

Autor

Participantes ajenos a IIS La Fe

De Bruycker A
Spiessens A
Dirix P
Koutsouvelis N
Semac I
Liefhooghe N
Gomez-Iturriaga A
Everaerts W
Otte F
Papachristofilou A
Scorsetti M
Shelan M
Siva S
Ameye F
Guckenberger M
Heikkilä R
Putora PM
Zapatero A
Couñago F
Vanhoutte F
Goetghebeur E
Reynders D
Zilli T
Ost P

Grupos

Investigación Clínica y Traslacional en Cáncer

Leader

José Gómez Codina

Abstract

Pelvic nodal recurrences are being increasingly diagnosed with the introduction of new molecular imaging techniques, like choline and PSMA PET-CT, in the restaging of recurrent prostate cancer (PCa). At this moment, there are no specific treatment recommendations for patients with limited nodal recurrences and different locoregional treatment approaches are currently being used, mostly by means of metastasis-directed therapies (MDT): salvage lymph node dissection (sLND) or stereotactic body radiotherapy (SBRT). Since the majority of patients treated with MDT relapse within 2 years in adjacent lymph node regions, with an estimated median time to progression of 12-18 months, combining MDT with whole pelvic radiotherapy (WPRT) may improve oncological outcomes in these patients. The aim of this prospective multicentre randomized controlled phase II trial is to assess the impact of the addition of WPRT to MDT and short-term androgen deprivation therapy (ADT) on metastasis-free survival (MFS) in the setting of oligorecurrent pelvic nodal recurrence.

Datos de la publicación

ISSN/ISSNe:: 1471-2407, 1471-2407
Tipo:: Article
Páginas:: 406-406
DOI:: 10.1186/s12885-020-06911-4
PubMed:: 32398040
Factor de Impacto:: 1,358 SCImago ℠
Cuartil:: Q2 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

De Bruycker A:: Department of Radiation oncology and experimental cancer research, Ghent University Hospital, Ghent, Belgium
Spiessens A:: Department of Radiation oncology and experimental cancer research, Ghent University Hospital, Ghent, Belgium
Dirix P:: Department of Radiation oncology, Iridium Cancer Network, GZ Antwerp, Antwerp, Belgium
Koutsouvelis N:: Department of Radiation oncology, Geneva University Hospital, Geneva, Switzerland
Semac I:: Department of Radiation oncology, Geneva University Hospital, Geneva, Switzerland

Clinical Research Center, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland
Liefhooghe N:: Department of Radiation oncology, AZ Groeninge, Kortrijk, Belgium
Gomez-Iturriaga A:: Cruces University Hospital (Biocruces Health Research Institute), Barakaldo, Spain
Everaerts W:: Department of Development and Regeneration, KU Leuven, Leuven, Belgium
Otte F:: Department of Radiation oncology, Jules Bordet Institute and Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Brussels, Belgium
Papachristofilou A:: Clinic of Radiotherapy & Radiation Oncology, University Hospital Basel, Basel, Switzerland
Scorsetti M:: Humanitas Clinical and Research Hospital, IRCSS, Radiotherapy and Radiosurgery Department, Rozzano, Milan, Italy
Shelan M:: Department of Radiation oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Siva S:: Epworth Healthcare, University of Melbourne, Melbourne, Australia
Ameye F:: Department of Urology, AZ Maria-Middelares Ghent, Ghent, Belgium
Guckenberger M:: Department of Radiation Oncology, University Hospital Zürich, University of Zurich, Zürich, Switzerland
Heikkilä R:: Department of Oncology, Oslo University Hospital, Oslo, Norway
Putora PM:: Department of Radiation oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Zapatero A:: University Hospital La Princesa, Madrid, Spain
Conde-Moreno A:: Department of Radiation oncology, Hospital Universitari i Politècnic la Fe, Valencia, Spain
Couñago F:: Department of Radiation oncology, University Hospital of Quirón, Madrid, Spain
Vanhoutte F:: Department of Radiation oncology and experimental cancer research, Ghent University Hospital, Ghent, Belgium
Goetghebeur E:: Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium
Reynders D:: Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium
Zilli T:: Department of Radiation oncology, Geneva University Hospital, Geneva, Switzerland.
Ost P:: Department of Radiation oncology and experimental cancer research, Ghent University Hospital, Ghent, Belgium.

Keywords

Androgen deprivation therapy, Metastasis-directed therapy, Oligometastases, Oligorecurrence, Prostate cancer, Quality of life, Salvage lymph node dissection, Stereotactic body radiotherapy, Survival, Whole pelvic radiotherapy

Campos de Estudio

Proyectos y Estudios Clínicos

ESTUDIO OBSERVACIONAL PARA DESCRIBIR RETROSPECTIVAMENTE LA EVOLUCIÓN DE LOS PACIENTES CON CÁNCER DE PRÓSTATA A LO LARGO DE LA ENFERMEDAD A TRAVÉS DE LA REUTILIZACIÓN DE LOS REGISTROS ELECTRÓNICOS DE SALUD CON INTELIGENCIA ARTIFICIAL. ESTUDIO OVERVIEW.

Investigador Principal: ANTONIO CONDE MORENO

JAN-CPR-2018-01 . 2018

GLIOMA DE BAJO GRADO CON MUTACIONES EN IDH Y 1P/19Q INTACTO TRAS LA RESECCIÓN: ¿ESPERAR O TRATAR? IWOT: ESTUDIO EN FASE III.

Investigador Principal: ANTONIO CONDE MORENO

1635-BTG . 2020

Cita

Cita Bibliográfica